I Hate Dialysis Message Board
Dialysis Discussion => Dialysis: News Articles => Topic started by: Falkenbach on February 08, 2008, 11:35:04 AM
-
From ninemsn.com.au
http://news.ninemsn.com.au:80/article.aspx?id=377371
Deadly new virus killed Melbourne women
Friday Feb 8 08:58 AEDT
By ninemsn staff and wires
Three Melbourne women who all mysteriously died within days of receiving body parts from the same donor were killed by previously unknown virus, research has revealed.
When the three women, ages 63, 64 and 44, all died in a Melbourne hospital after receiving a liver and two kidneys from the same man, doctors were baffled and knew something extremely unusual had occurred.
But the Victoria Infectious Diseases Reference Laboratory (VIDRL) could not find a cause and asked a team of experts at New York’s Colombia University for help.
The US researchers found the women died after contracting a previously unknown virus that appeared to be related to a bug called lymphocytic choriomeningitis virus, which usually causes only a minor flu-like illness.
But this one killed the three transplant patients by causing encephalitis, a swelling of the brain.
"That donor died of a stroke and was not thought to have had an infectious disease at all," said Dr Ian Lipkin of Columbia University, who led the study, which was published yesterday in the New England Journal of Medicine.
The 57-year-old donor had recently visited the former Yugoslavia before dying of a cerebral haemorrhage in Australia, and Lipkin's team said the virus looked like it was of "Old World" origin.
VIDRL director Dr Mike Catton told ABC radio the Colombia University researchers had made a rare and important discovery.
“It's a brand new virus. A new technology for finding a virus and in the background a tragic cluster of deaths that alerted us to something that was rare and highly significant.”
“It was extraordinarily difficult finding this virus. The equivalent of finding a needle in the haystack,” he said.
The researchers used a relatively new method to find the virus, called high-throughput sequencing. They used powerful machines to get the full genetic sequences from the organs and from the patients, and filtered out everything but the sequences from the virus.
Traditional methods such as trying to grow a virus or bacteria from samples, and even standard DNA sequencing, failed to turn up anything.
"As a result, the samples were sent to us," Lipkin said in a telephone interview.
His team used a new machine — a high-throughput sequencer made by 454 Life Sciences, a part of Roche Applied Science and Roche AG.
These machines are usually used to mass-sequence entire genomes of large organisms, such as humans. It had never been used on a hunt like this one.
"After 100,000 different sequence analyses we found 14 (suspicious viral genetic sequences)," Lipkin said. "So it was a needle-in-a-haystack problem."
The RNA resembled the RNA from a type of virus known as an arenavirus, specifically lymphocytic choriomeningitis virus or LCMV, known to cause transplant-related disease and birth defects in addition to mild flu-like illness in healthy people.
"The virus is new and was not detected in 100 organ recipients who were not linked to this cluster," the researchers wrote.
Lipkin said the method may be useful for diagnosing mysterious new ailments.
"We have so many diseases where there is no agent implicated," he said. "Over half of pneumonia and over half of encephalitis and over half of diarrheal disease are never diagnosed," he added.
"We need to be able to survey for old and new agents."
Christopher McLeod, president of 454 Life Sciences, said the machine might help identify emerging new infections, like the severe acute respiratory syndrome, or SARS, virus that appeared suddenly in China in 2002 and killed nearly 800 people globally before it was contained two years later.
"Over 30,000 organ transplants are performed in the US each year. Knowledge of the genetic sequence of this virus might enable improvements in screening that will enhance the safety of transplantation," McLeod said in a statement.